We are monitoring the impact of COVID-19 on Next Generation Antibody Therapeutics Market Get in touch with us for detailed analysis Know More
Pulished Date April, 2021
ID: 5220
Share on
Share on

Global Next Generation Antibody Therapeutics Market Size, Share, Trends, Growth & COVID-19 Impact Analysis Report – Segmented By Therapeutics, Technology & Region - Industry Forecast (2021 to 2026)

Pulished: April, 2021
ID: 5220
Pages: 175

Next Generation Antibody Therapeutics Market Size (2021 to 2026):

The size of the global next generation antibody therapeutics market was worth USD 4.33 billion in 2021 and is expected to grow with a CAGR of 13% to reach USD 7.97 billion by 2026.

Next-generation antibody therapeutics are used to treat various critical medical conditions like cancer, infectious diseases, and immune diseases.

MARKET DRIVERS:

Y-O-Y growth in the prevalence of cancer, technological advancements, and rising geriatric population across the world is expected to drive growth to the global next-generation antibody therapeutics market.

Growing investments from the biopharmaceutical and pharmaceutical companies to develop effective antibodies to treat diseases such as autoimmune, inflammatory, and chronic are expected to fuel the growth rate of the market. The rise in the population aging above 65 years is significantly growing across various parts of the world, which is expected to increase the demand levels for the next generation antibody therapeutics during the forecast period.

Growing incidence of such as cancer and asthma are further promoting the global next generation antibody therapeutics market. According to the Asthma and Allergy Foundation of America (AAFA), an estimated 25 million Americans have asthma, which is 1 in 13 Americans. The numbers are increasing year-by-year. Growing discovery and development activities of monoclonal antibodies is another significant factor boosting the global next generation antibody therapeutics market.

Furthermore, technological advancements, growing R&D activities, and raising funds and investments from the governments dedicated to the antibody therapeutics sector are propelling the market growth.

MARKET RESTRAINTS:

High costs associated with the antibody’s treatment is one primary factor hampering the next generation antibody therapeutics market growth.

Complexities associated with the product approvals and strict regulatory forms for manufacturing drugs are expected to restrain the global next-generation antibody therapeutics market growth. Lack of awareness among the patients is further estimated to impedes the market.

Impact of COVID-19 on the global next-generation antibody therapeutics market:

The sudden outburst of novel coronavirus caused by the SARS-CoV-2 originated in China, Wuhan, in December 2019. The virus has caused millions of human infections and deaths. For recovery from this airborne infectious disease, antibody-based therapy treatment is one of the treatment choices. CT-P59 (regdanvimab) a monoclonal antibody to combat coronavirus disease. The antibodies aimed to treat patients with gentle to severe COVID-19 in adults tested positive. Patients treated with CT-P50 present a considerably decreased threat of COVID 19 associated hospitalization and oxygenation without death. Due to the COVID-19, the usage of antibodies has increased, and the market has seen an acceleration in its growth rate. Similarly, the global next generation antibody therapeutics market is expected to experience significant growth during the forecast period.

REPORT COVERAGE:

REPORT METRIC

DETAILS

Market Size Available

2021 to 2026

Base Year

2020

Forecast Period

2021 to 2026

Segments Covered

By Therapeutics, Technology, and Region

Various Analyses Covered

Global, Regional & Country Level Analysis, Segment-Level Analysis, Drivers, Restraints, Opportunities, Challenges, PESTLE Analysis, Porter’s Five Forces Analysis, Competitive Landscape, Analyst Overview on Investment Opportunities

Regions Covered

North America, Europe, Asia Pacific, Latin America, Middle East & Africa

 

This market research report on the global next-generation antibody therapeutics market has been segmented based on the therapeutics, technology, and region.

Next Generation Antibody Therapeutics Market – By Therapeutics:

  • Oncology
  • Autoimmune/Inflammatory Diseases

The oncology segment is expected to account for the largest share in the next generation antibody therapeutics market during the forecast period based on the therapeutics. Cancer accounts for nearly 13% of deaths globally every year, and the mortality rate of cancer is likely to increase at a higher rate in the coming years.

The Autoimmune/Inflammatory diseases segment is predicted to grow at a healthy rate during the forecast period.

Next Generation Antibody Therapeutics Market – By Technology:

  • Antibody-Drug Conjugates (ADCs)
  • Bispecific Antibodies (BsAbs)
  • Fc Engineered Antibodies
  • Antibody Fragments
  • Antibody-like Proteins
  • Biosimilar Antibody Products

Based on the technology, the antibody-drug conjugates (ADCs) are projected to lead the global next generation antibody therapeutics market during the forecast period with more than 50% occupancy. The Fc engineered antibodies segment is anticipated to have a healthy CAGR in the global next generation antibody therapeutics market during the forecast period.

Next-Generation Antibody Therapeutics Market - By Region:

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • The Middle East and Africa

Geographically, the North America Next-Generation Antibody Therapeutics Market is was the most dominating regional market globally in 2020 and forecasted to continue the domination throughout the forecast period due to large funds and investments for research and development. Escalation of the elder people population, the growing frequency of chronic diseases is anticipated to boost the market growth in this region. The United States, followed by Canada, is expected to dominate this regional market between 2021 to 2026.

The Europe Next-Generation Antibody Therapeutics Market is estimated to be the second-largest regional market worldwide during the forecast period. Factors such as technological advancements, a growing number of collaborations among the key market participants, developments in the life sciences research infrastructure, growing applications for such therapies, and government support are expected to drive this regional market.

The Asia-Pacific Next-Generation Antibody Therapeutics Market is expected to register with the highest CAGR among all the regions during the forecast period. Growing demand from developing countries such as India and China is a significant growth driver to this regional market. Additionally, the growing incidence of various diseases and rising support from the Asian governments to develop effective therapeutic antibodies favor the market.

The Latin America Next-Generation Antibody Therapeutics Market is projected to grow at a steady rate during the forecast period due to the growing aging population, urbanization, and lifestyle changes.

The MEA Next-Generation Antibody Therapeutics Market is anticipated to grow at a sluggish rate during the forecast period due to the growing occurrence rate of cancer and developments in monoclonal antibody technologies.

KEY MARKET PARTICIPANTS:

Notable companies dominating the global next-generation antibody therapeutics market profiled in the report are Roche, Seattle Genetics, Takeda, Dyax Corp, Immunogen, Amgen, Inc., Biogen, Kyowa Hakko Kirin Co., Ltd., AstraZeneca, Pfizer, Inc. and Xencor, Inc.

RECENT MARKET DEVELOPMENTS:

  • In February 2020, Xencor, Inc. received the license to develop the investigational humanized monoclonal antibody XmAb 7195 to Aimmune therapeutics to treat cancer autoimmune diseases.
  • In July 2019, REGENXBIO and Neurimmune AG announced the license, development, and commercialization of agreement to invent and develop new AAV gene therapies using NAV vectors to deliver human antibodies against chronic neurodegenerative diseases, which include tauopathies.
  • In May 2020, Takeda pharmaceuticals announced the US FDA acceptance of ALUNBRIG for adult patients with anaplastic lymphoma kinase positive (ALK+) metastatic non-small lung cancer.

1. Introduction        

                1.1 Market Definition                    

                1.2 Study Deliverables                  

                1.3 Base Currency, Base Year and Forecast Periods 

                1.4 General Study Assumptions                

2. Research Methodology                  

                2.1 Introduction      

                2.2 Research Phases                      

       2.2.1 Secondary Research           

       2.2.2 Primary Research 

       2.2.3 Econometric Modelling      

       2.2.4 Expert Validation  

                2.3 Analysis Design

                2.4 Study Timeline 

3. Overview              

                3.1 Executive Summary                

                3.2 Key Inferences

                3.3 Epidemiology     

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)           

                4.1 Market Drivers 

                4.2 Market Restraints                    

                4.3 Key Challenges

                4.4 Current Opportunities in the Market     

5. Market Segmentation                     

                5.1 Technology                 

                           5.1.1 Introduction           

       5.1.2 Antibody-Drug Conjugates (ADCs)               

       5.1.3 Bispecific Antibodies (BsAbs)          

       5.1.4 Fc Engineered Antibodies 

       5.1.5 Antibody Fragments and Antibody-like Proteins    

       5.1.6 Biosimilar Antibody Products          

       5.1.7 Y-o-Y Growth Analysis, By Technology        

       5.1.8 Market Attractiveness Analysis, By Technology      

       5.1.9 Market Share Analysis, By Technology        

                5.2 Therapeutic Application                        

       5.2.1 Introduction           

       5.2.2 Oncology 

       5.2.3 Autoimmune/Inflammatory Diseases         

       5.2.4 Y-o-Y Growth Analysis, By Therapeutic Application               

       5.2.5 Market Attractiveness Analysis, By Therapeutic Application             

       5.2.6 Market Share Analysis, By Therapeutic Application               

6. Geographical Analysis                     

                6.1 Introduction      

       6.1.1 Regional Trends    

       6.1.2 Impact Analysis     

       6.1.3 Y-o-Y Growth Analysis        

                       6.1.3.1 By Geographical Area

                       6.1.3.2 By Technology

                       6.1.3.3 By Therapeutic Application

       6.1.4  Market Attractiveness Analysis     

                       6.1.4.1 By Geographical Area

                       6.1.4.2 By Technology

                       6.1.4.3 By Therapeutic Application

       6.1.5  Market Share Analysis      

                       6.1.5.1 By Geographical Area

                       6.1.5.2 By Technology

                       6.1.5.3 By Therapeutic Application

                6.2 North America

       6.2.1 Introduction           

       6.2.2 United States         

       6.2.3 Canada     

                6.3 Europe                         

       6.3.1 Introduction           

       6.3.2 U.K             

       6.3.3 Spain         

       6.3.4 Germany 

       6.3.5 Italy            

       6.3.6 France       

                6.4 Asia-Pacific                 

       6.4.1 Introduction           

       6.4.2 China         

       6.4.3 India          

       6.4.4 Japan         

       6.4.5 Australia   

       6.4.6 South Korea           

                6.5 Latin America    

       6.5.1 Introduction           

       6.5.2 Brazil          

       6.5.3 Argentina

       6.5.4 Mexico     

       6.5.5 Rest of Latin America          

                6.6 Middle East & Africa      

       6.5.1 Introduction           

       6.5.2 Middle-East            

       6.5.3 Africa         

7. Strategic Analysis              

                7.1 PESTLE analysis

       7.1.1 Political     

       7.1.2 Economic 

       7.1.3 Social         

       7.1.4 Technological         

       7.1.5 Legal          

       7.1.6 Environmental       

                7.2 Porter’s Five analysis     

       7.2.1 Bargaining Power of Suppliers        

       7.2.2 Bargaining Power of Consumers    

       7.2.3 Threat of New Entrants     

       7.2.4 Threat of Substitute Products and Services              

       7.2.5 Competitive Rivalry within the Industry     

8. Market Leaders' Analysis               

                8.1 Roche  

       8.1.1 Overview 

       8.1.2 Product Analysis   

       8.1.3 Financial analysis  

       8.1.4 Recent Developments       

       8.1.5 SWOT analysis       

       8.1.6 Analyst View          

                8.2 Seattle Genetics                       

                8.3 Takeda

                8.4 Dyax Corp.                  

                8.5 Immunogen      

                8.6 Amgen, Inc.       

                8.7 Biogen 

                8.8 Kyowa Hakko Kirin Co., Ltd.                 

                8.9 AstraZeneca      

                8.10 Pfizer, Inc.                

9. Competitive Landscape                  

                9.1 Market share analysis   

                9.2 Merger and Acquisition Analysis                       

                9.3 Agreements, Collaborations, and Joint Ventures

                9.4 New Product Launches

10. Market Outlook and Investment Opportunities                

Appendix                  

                a) List of Tables                

                b) List of Figures     

  • Global, regional and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
  • Segment-level analysis in terms product type market size forecasts and estimations to detect key areas of industry growth in detail
  • Identification of key drivers, restraints, opportunities and challenges (DROC) in the market and their impact on shifting market dynamics
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
  • Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analyzing the level of competition and business strategy development
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market
  1. Global Next-Generation Antibody Therapeutics Market By Region, From 2021 to 2026 ( USD Billion )
  2. Global Next-Generation Antibody Therapeutics Market By Technology, From 2021 to 2026 ( USD Billion )
  3. Global Antibody-Drug Conjugates (ADCs) Market By Region, From 2021 to 2026 ( USD Billion )
  4. Global Bispecific Antibodies (BsAbs)  Market By Region, From 2021 to 2026 ( USD Billion )
  5. Global Fc Engineered Antibodies Market By Region, From 2021 to 2026 ( USD Billion )
  6. Global Antibody Fragments and Antibody-like Proteins Market By Region, From 2021 to 2026 ( USD Billion )
  7. Global Biosimilar Antibody Products Market By Region, From 2021 to 2026 ( USD Billion )
  8. Global Next Generation Antibody Therapeutics Market By Therapeutic Application, From 2021 to 2026 ( USD Billion )
  9. Global Oncology Market By Region, From 2021 to 2026 ( USD Billion )
  10. Global Autoimmune/Inflammatory Diseases Market By Region, From 2021 to 2026 ( USD Billion )
  11. North America Next Generation Antibody Therapeutics Market By Technology, From 2021 to 2026 ( USD Billion )
  12. North America Antibody-Drug Conjugates (ADCs) Market By Region, From 2021 to 2026 ( USD Billion )
  13. North America Bispecific Antibodies (BsAbs)  Market By Region, From 2021 to 2026 ( USD Billion )
  14. North America Fc Engineered Antibodies Market By Region, From 2021 to 2026 ( USD Billion )
  15. North America Antibody Fragments and Antibody-like Proteins Market By Region, From 2021 to 2026 ( USD Billion )
  16. North America Biosimilar Antibody Products Market By Region, From 2021 to 2026 ( USD Billion )
  17. North America Next Generation Antibody Therapeutics Market By Therapeutic Application, From 2021 to 2026 ( USD Billion )
  18. North America Oncology Market By Region, From 2021 to 2026 ( USD Billion )
  19. North America Autoimmune/Inflammatory Diseases Market By Region, From 2021 to 2026 ( USD Billion )
  20. United States Next Generation Antibody Therapeutics Market By Technology, From 2021 to 2026 ( USD Billion )
  21. United States Next Generation Antibody Therapeutics Market By Therapeutic Application, From 2021 to 2026 ( USD Billion )
  22. Canada Next Generation Antibody Therapeutics Market By Technology, From 2021 to 2026 ( USD Billion )
  23. Canada Next Generation Antibody Therapeutics Market By Therapeutic Application, From 2021 to 2026 ( USD Billion )
  24. Europe Next Generation Antibody Therapeutics Market By Technology, From 2021 to 2026 ( USD Billion )
  25. Europe Antibody-Drug Conjugates (ADCs) Market By Region, From 2021 to 2026 ( USD Billion )
  26. Europe Bispecific Antibodies (BsAbs)  Market By Region, From 2021 to 2026 ( USD Billion )
  27. Europe Fc Engineered Antibodies Market By Region, From 2021 to 2026 ( USD Billion )
  28. Europe Antibody Fragments and Antibody-like Proteins Market By Region, From 2021 to 2026 ( USD Billion )
  29. Europe Biosimilar Antibody Products Market By Region, From 2021 to 2026 ( USD Billion )
  30. Europe Next Generation Antibody Therapeutics Market By Therapeutic Application, From 2021 to 2026 ( USD Billion )
  31. Europe Oncology Market By Region, From 2021 to 2026 ( USD Billion )
  32. Europe Autoimmune/Inflammatory Diseases Market By Region, From 2021 to 2026 ( USD Billion )
  33. U.K. Next Generation Antibody Therapeutics Market By Technology, From 2021 to 2026 ( USD Billion )
  34. U.K. Next Generation Antibody Therapeutics Market By Therapeutic Application, From 2021 to 2026 ( USD Billion )
  35. Germany Next Generation Antibody Therapeutics Market By Technology, From 2021 to 2026 ( USD Billion )
  36. Germany Next Generation Antibody Therapeutics Market By Therapeutic Application, From 2021 to 2026 ( USD Billion )
  37. France Next Generation Antibody Therapeutics Market By Technology, From 2021 to 2026 ( USD Billion )
  38. France Next Generation Antibody Therapeutics Market By Therapeutic Application, From 2021 to 2026 ( USD Billion )
  39. Italy Next Generation Antibody Therapeutics Market By Technology, From 2021 to 2026 ( USD Billion )
  40. Italy Next Generation Antibody Therapeutics Market By Therapeutic Application, From 2021 to 2026 ( USD Billion )
  41. Spain Next Generation Antibody Therapeutics Market By Technology, From 2021 to 2026 ( USD Billion )
  42. Spain Next Generation Antibody Therapeutics Market By Therapeutic Application, From 2021 to 2026 ( USD Billion )
  43. Asia Pacific Next Generation Antibody Therapeutics Market By Technology, From 2021 to 2026 ( USD Billion )
  44. Asia Pacific Antibody-Drug Conjugates (ADCs) Market By Region, From 2021 to 2026 ( USD Billion )
  45. Asia Pacific Bispecific Antibodies (BsAbs)  Market By Region, From 2021 to 2026 ( USD Billion )
  46. Asia Pacific Fc Engineered Antibodies Market By Region, From 2021 to 2026 ( USD Billion )
  47. Asia Pacific Antibody Fragments and Antibody-like Proteins Market By Region, From 2021 to 2026 ( USD Billion )
  48. Asia Pacific Biosimilar Antibody Products Market By Region, From 2021 to 2026 ( USD Billion )
  49. Asia Pacific Next Generation Antibody Therapeutics Market By Therapeutic Application, From 2021 to 2026 ( USD Billion )
  50. Asia Pacific Oncology Market By Region, From 2021 to 2026 ( USD Billion )
  51. Asia Pacific Autoimmune/Inflammatory Diseases Market By Region, From 2021 to 2026 ( USD Billion )
  52. Japan Next Generation Antibody Therapeutics Market By Technology, From 2021 to 2026 ( USD Billion )
  53. Japan Next Generation Antibody Therapeutics Market By Therapeutic Application, From 2021 to 2026 ( USD Billion )
  54. China Next Generation Antibody Therapeutics Market By Technology, From 2021 to 2026 ( USD Billion )
  55. China Next Generation Antibody Therapeutics Market By Therapeutic Application, From 2021 to 2026 ( USD Billion )
  56. India Next Generation Antibody Therapeutics Market By Technology, From 2021 to 2026 ( USD Billion )
  57. India Next Generation Antibody Therapeutics Market By Therapeutic Application, From 2021 to 2026 ( USD Billion )
  58. Australia Next Generation Antibody Therapeutics Market By Technology, From 2021 to 2026 ( USD Billion )
  59. Australia Next Generation Antibody Therapeutics Market By Therapeutic Application, From 2021 to 2026 ( USD Billion )
  60. South Korea Next Generation Antibody Therapeutics Market By Technology, From 2021 to 2026 ( USD Billion )
  61. South Korea Next Generation Antibody Therapeutics Market By Therapeutic Application, From 2021 to 2026 ( USD Billion )
  62. Latin America Next Generation Antibody Therapeutics Market By Technology, From 2021 to 2026 ( USD Billion )
  63. Latin America Antibody-Drug Conjugates (ADCs) Market By Region, From 2021 to 2026 ( USD Billion )
  64. Latin America Bispecific Antibodies (BsAbs)  Market By Region, From 2021 to 2026 ( USD Billion )
  65. Latin America Fc Engineered Antibodies Market By Region, From 2021 to 2026 ( USD Billion )
  66. Latin America Antibody Fragments and Antibody-like Proteins Market By Region, From 2021 to 2026 ( USD Billion )
  67. Latin America Biosimilar Antibody Products Market By Region, From 2021 to 2026 ( USD Billion )
  68. Latin America Next Generation Antibody Therapeutics Market By Therapeutic Application, From 2021 to 2026 ( USD Billion )
  69. Latin America Oncology Market By Region, From 2021 to 2026 ( USD Billion )
  70. Latin America Autoimmune/Inflammatory Diseases Market By Region, From 2021 to 2026 ( USD Billion )
  71. Brazil Next Generation Antibody Therapeutics Market By Technology, From 2021 to 2026 ( USD Billion )
  72. Brazil Next Generation Antibody Therapeutics Market By Therapeutic Application, From 2021 to 2026 ( USD Billion )
  73. Argentina Next Generation Antibody Therapeutics Market By Technology, From 2021 to 2026 ( USD Billion )
  74. Argentina Next Generation Antibody Therapeutics Market By Therapeutic Application, From 2021 to 2026 ( USD Billion )
  75. Mexico Next Generation Antibody Therapeutics Market By Technology, From 2021 to 2026 ( USD Billion )
  76. Mexico Next Generation Antibody Therapeutics Market By Therapeutic Application, From 2021 to 2026 ( USD Billion )
  77. Rest of Latin America Next Generation Antibody Therapeutics Market By Technology, From 2021 to 2026 ( USD Billion )
  78. Rest of Latin America Next Generation Antibody Therapeutics Market By Therapeutic Application, From 2021 to 2026 ( USD Billion )
  79. Middle East and Africa Next Generation Antibody Therapeutics Market By Technology, From 2021 to 2026 ( USD Billion )
  80. Middle East and Africa Antibody-Drug Conjugates (ADCs) Market By Region, From 2021 to 2026 ( USD Billion )
  81. Middle East and Africa Bispecific Antibodies (BsAbs)  Market By Region, From 2021 to 2026 ( USD Billion )
  82. Middle East and Africa Fc Engineered Antibodies Market By Region, From 2021 to 2026 ( USD Billion )
  83. Middle East and Africa Antibody Fragments and Antibody-like Proteins Market By Region, From 2021 to 2026 ( USD Billion )
  84. Middle East and Africa Biosimilar Antibody Products Market By Region, From 2021 to 2026 ( USD Billion )
  85. Middle East and Africa Next Generation Antibody Therapeutics Market By Therapeutic Application, From 2021 to 2026 ( USD Billion )
  86. Middle East and Africa Oncology Market By Region, From 2021 to 2026 ( USD Billion )
  87. Middle East and Africa Autoimmune/Inflammatory Diseases Market By Region, From 2021 to 2026 ( USD Billion )
  88. Middle East Next Generation Antibody Therapeutics Market By Technology, From 2021 to 2026 ( USD Billion )
  89. Middle East Next Generation Antibody Therapeutics Market By Therapeutic Application, From 2021 to 2026 ( USD Billion )
  90. Africa Next Generation Antibody Therapeutics Market By Technology, From 2021 to 2026 ( USD Billion )
  91. Africa Next Generation Antibody Therapeutics Market By Therapeutic Application, From 2021 to 2026 ( USD Billion )

Please wait. . . . Your request is being processed

Related Reports

LICENCE TYPE

$ 1234 4255

Clients
clients
clients
clients
clients
clients
clients
Click for Request Sample